Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) has commenced an underwritten public offering of $300 million of its common stock. The company also plans to grant underwriters a 30‑day option to purchase up to an additional $45 million of common shares.
All shares in the proposed offering will be sold by Dyne. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital and Raymond James are acting as joint book‑running managers, with Jones as lead manager. The transaction is being conducted under an automatically effective Form S‑3 shelf registration filed on March 5, 2024, and remains subject to market and other conditions, with final terms to be disclosed in a forthcoming final prospectus supplement filed with the SEC.
Positive
- $300 million primary common stock offering commenced, plus $45 million underwriter option
- Effective Form S-3 shelf filed March 5, 2024 enables swift capital raise
Negative
- All-new common stock issuance implies potential dilution for existing shareholders
- Offering size and terms not yet final, subject to market and other conditions
News Explained
If completed, the proposed share sale would dilute existing ownership; its $300 million headline is gross, with final size and terms unsettled.
Because Dyne is selling the shares itself, the commenced offering would add common shares and reduce existing holders’ percentage ownership if completed, while the company would receive the sale proceeds before underwriting fees.
As an underwritten offering, investment banks would buy and resell the shares, with fees reducing cash retained below the stated gross amount; the additional
Using first-quarter 2026 operating cash use as the comparison basis, the proposed gross amount equals
The final prospectus supplement is the named checkpoint for the offering’s final size, price and fees, while the release says completion and actual terms remain subject to conditions.
Sources and calculations
- Dyne proposed public offering release (2026-07-21)
- Dilution definition (2026-07-17)
- Underwritten offering definition (2026-07-17)
- Prospectus supplement purpose (2026-07-17)
- Dyne first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $300,000,000 / ($144,922,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $753,102,000 / ($144,922,000 / 90) = [object Object]
News Market Reaction – DYN
In the Jul 22 session, DYN declined 2.60%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Offering closing | Negative | -0.8% | Closed upsized common-stock offering after full exercise of underwriters’ option |
| Dec 09 | Offering pricing | Negative | +6.8% | Priced upsized common-stock offering expected to raise $350.0 million |
| Dec 08 | Proposed offering | Negative | -16.9% | Commenced $300.0 million offering with additional $45.0 million option |
| Jul 02 | Offering closing | Negative | -2.0% | Completed $230.0 million common-stock offering including underwriters’ option |
| Jun 30 | Offering pricing | Negative | -8.8% | Priced 24,242,425-share offering at $8.25 per share |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-tagged events generally aligned with negative 24-hour reactions, with an average move of -4.35%, although one event diverged positively.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
joint book-running managers financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of
Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting as joint book-running managers for the offering. Jones is acting as lead manager for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering is expected to be filed with the SEC and, if and when filed, copies of the preliminary prospectus supplement relating to the offering may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com; or Raymond James & Associates, Inc., at 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, by calling toll-free at 1-800-248-8863, or emailing at prospectus@raymondjames.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the proposed underwritten public offering, the anticipated terms of the proposed offering, market and other conditions relating to the offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement to be filed with the SEC, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
